

1 Article

2 **Fisetin, a 3, 7, 3', 4'-tetrahydroxyflavone inhibits**  
 3 **PI3K/Akt/mTOR and MAPK Pathways and**  
 4 **Ameliorates Psoriasis Pathology in 2D and 3D**  
 5 **Organotypic Human Inflammatory Skin Models**


6

7 Jean Christopher Chamcheu<sup>1,\*</sup>, Stephane Esnault<sup>2</sup>, Vaqar M. Adhami<sup>3</sup>, Andrea L. Noll<sup>2</sup>,  
 8 Sergette Banang-Mbeumi<sup>1,†</sup>, Tithi Roy<sup>1</sup>, Sitanshu S. Singh<sup>1</sup>, Shile Huang<sup>4,5</sup>, Konstantin Gus  
 9 Kousoulas<sup>6</sup>, and Hasan Mukhtar<sup>2</sup>

10

11 **Supplementary Materials:**


12



13

14 **Figure S1:** Fisetin significantly and dose-dependently suppressed the IL-22 induced proliferation  
 15 of 2D culture NHEKs by MTT assay, compared with precancerous (HaCaT) and cancer (A431) cell  
 16 lines (\*\* $p < 0.05$  to \*\*\* $p < 0.001$ ).

17



18  
19  
20  
21  
22  
23  
24  
25

**Figure S2:** Representative photomicrographs of immunofluorescent staining showing the protein expression levels of differentiation marker (TGase-1) in control (RHSE) and FTRHSP conditions versus (fisetin or vit-D<sub>3</sub>)-treated FTRHSP tissues. Data green (TGase-1); blue (DAPI) and mixed staining is merged representation. Results are representative of three independent experiments each performed in quadruplicate and comparing control RHSE vs treated FTRHSP. TGase-1 = transglutaminase-1. Scale Bar = 20 μm.